Product Description
Mechanisms of Action: ADRA1A Agonist, ADRA1B Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Approved
Approved Countries: Bangladesh | India | Italy | Korea | Pakistan | United States
Approved Indications: None
Known Adverse Events: None
Company: eGenesis, INC
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Acute-On-Chronic Liver Failure|Hepatic Encephalopathy|Liver Failure, Acute
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT07429838 |
EGEN-5784-CL-1001 | P1 |
Not yet recruiting |
Liver Failure, Acute|Hepatic Encephalopathy|Acute-On-Chronic Liver Failure |
2027-12-15 |
50% |
2026-02-25 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/20/2025 |
News Article |
Anti-Obesity Drug Market to Reach USD 82.55 Billion in 2032, Exclusive Report by Coherent Market Insights |
|
04/16/2025 |
News Article |
Best Appetite Suppressants - Natural Over the Counter (OTC) Appetite Suppressant for Hunger Control & Fat Burner ( Men & Women) - By Phenq CrazyBulk in USA |